USA-based Curis, which develops products based on technologies in theemerging field of regenerative medicines, has been added to the list of companies making up the Russell 2000 and 3000 indexes.
The company's chief executive, Doros Platika, said: "our inclusion represents another significant milestone and, more importantly, an acknowledgement of the technologic value we have been able to create at Curis," and reflects the "growing recognition of regenerative medicine and its potential clinical and commercial value."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze